PhysBizTech (02.05.13)
Following the US Food and Drug Administration’s (FDA’s) official announcement on January 18 of a doxycycline shortage, quantities of the drug remain in short supply. The decreased availability is due in part to both manufacturing delays and use of the drug as a primary treatment for many sexually transmitted diseases such as chlamydia, nongonococcal urethritis, epididymitis, and pelvic inflammatory disease. CDC has provided a series of alternative treatment options for physicians to consider for their patients at http://www.cdc.gov/std/treatment/doxycyclineShortage.htm. FDA has listed additional information on manufacturer status regarding the antibiotic, contact information, and other commentary at http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm#doxycycline.